Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-00610355 · 3 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| PF-00610355 | EXPERIMENTAL | - |
| PF- 00610355 | EXPERIMENTAL | - |
| PF - 00610355 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Salmeterol | ACTIVE_COMPARATOR | - |
| PF -00610355 | EXPERIMENTAL | - |
| PF-00610355 450 µg | EXPERIMENTAL | An orally inhaled dose of PF-00610355 450 µg |
| PF-00610355 1200 µg | EXPERIMENTAL | An orally inhaled dose of PF-00610355 1200 µg |
| moxifloxacin 400 mg | ACTIVE_COMPARATOR | A single oral dose of moxifloxacin 400 mg on Day 4. |
| Name | Type | Description |
|---|---|---|
| PF-00610355 | DRUG | oral, inhaled, dry powder, 600ug, OD |
| PF - 00610355 | DRUG | oral, inhaled, dry powder, 300ug, OD |
| PF- 00610355 | DRUG | oral, inhaled, dry powder, 100ug, OD |
| Placebo | DRUG | oral, inhaled, dry powder, placebo, OD |
| Salmeterol | DRUG | salmeterol, 50ug, BID |
| moxifloxacin | DRUG | A single oral dose of moxifloxacin 400 mg on Day 4. |
Inclusion Criteria: * Post-bronchodilator FEV1/FVC ratio \<0.7 and a post-bronchodilator FEV1 of 50-80%. * Diagnosis of moderate COPD for a minimum of 6 months. * Stable disease for at least 1 month prior to screening Exclusion Criteria: * More than 2 exacerbations of COPD requiring treatment wit...
PF-00610355 is an investigational small molecule being developed for the treatment of chronic obstructive pulmonary disease (COPD). It has been studied in clinical trials involving COPD patients to evaluate its safety, toleration, and efficacy. The drug is administered via inhalation and is currently in clinical development, though it is not yet approved.
PF-00610355 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. Pfizer has conducted multiple clinical trials to investigate the drug's safety and efficacy in patients with chronic obstructive pulmonary disease.
PF-00610355 is in Phase 1 clinical development. While some completed trials were designated as Phase 2, the overall development stage is Phase 1. The drug is investigational and has not been approved by regulatory authorities. All clinical trials for PF-00610355 have been completed, with no active trials currently ongoing.
PF-00610355 has been studied in three completed clinical trials. NCT00783406 and NCT00808288 evaluated the drug in COPD patients, while NCT01107054 investigated its effects on the QT/QTc interval in healthy volunteers. These trials were conducted in multiple countries, including the United States, Germany, and Belgium.
No, PF-00610355 and PF00610335 are different compounds. A clinical trial (NCT01107054) investigated the effects of PF00610335 on the QT/QTc interval in healthy volunteers, but this is a separate drug from PF-00610355, which is being studied for chronic obstructive pulmonary disease.